Introduction to Acute Hepatic Porphyria Drugs
Acute hepatic porphyria drugs are used for the treatment of adult patients with acute hepatic porphyria. Acute hepatic porphyria’s (AHPs) are a family of rare, genetic diseases characterized by potentially life-threatening attacks and, for many patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life. Panhematin is a one of the acute hepatic porphyria drugs. Acute hepatic porphyria arises as a result of a malfunction in one of the eight steps in the body's synthesis of a complex molecule called heme. The most common symptoms are severe abdominal pain, nausea, vomiting, and constipation.
Market Size and Forecast
The acute hepatic porphyria drugs market is thriving on the back of growing awareness among the people regarding this disease coupled with the growing research activities. The acute hepatic porphyria drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by product type, by application and by end user. The application segment is further segmented into hospitals, pharmacies, clinics and others. Based on this, the segment for hospitals is anticipated to hold the leading share in the market on account of availability of porphyria medicines used for the patient’s treatment only at the hospital under the doctors’ supervision.
Growth Drivers
Increasing Prevalence of Rare Metabolic and Genetic Disease to Boost the Market Growth
Since the incidence rate of rare metabolic disorders such as acute hepatic porphyria have been growing in the past few year, the demand for acute hepatic porphyria drugs is increasing. According to U.S. National Library of Medicines (Genetic Home Reference), the prevalence of porphyria ranges from 1 in 500 to 1 in 50,000 people worldwide and acute intermittent porphyria (AIP) is the most common form of acute hepatic porphyria in most countries. This is anticipated to significantly expand the acute hepatic porphyria drugs market.
Expanding Healthcare R&D and Increase in Awareness to Drive the Market Growth
The expanding growth in pharmaceutical as well as biotechnology industries all over the world is improving at a fast pace owing to the increasing number of cases of various diseases. Further, there is an increased awareness among people regarding acute hepatic porphyria owing to the fact that it primarily affects the nervous system and other major organs. The growing research and development for better treatment methods at research laboratories further fuels the healthcare industry. On the back of these, the market is predicted to grow over the forecast period.
Restraints
High Treatment Costs and Lack of Reimbursement Facilities to Hamper the Market Growth
Despite the improving healthcare infrastructure, there is a high cost associated with this drug used for the treatment of this disease. In addition to this, the poor reimbursement policies in the developing countries is estimated to hinder the growth of acute hepatic porphyria drugs market in the future.
Market Segmentation
Our in-depth analysis of the acute hepatic porphyria drugs market includes the following segments:
By Product Type
- 350 Mg
- 313 Mg
By Application
- 5â€Aminolevulinic Acid Dehydratase [ALAD] Deficiency Porphyria
- Acute Intermittent Porphyria [AIP]
- Hereditary Coproporphyria [HCP]
- Variegate Porphyria [VP]
By End User
- Hospitals
- Pharmacies
- Clinics
- Others
By Region
On the basis of regional analysis, the acute hepatic porphyria drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
The market for acute hepatic porphyria drugs in North America is anticipated to hold the largest share in the market on account of presence of leading market players in the region which manufacture and market acute hepatic porphyria drugs. Moreover, support from government in implementation of advanced healthcare technologies coupled with the rise in patients with genetic metabolic disorders in the region further increases the product demand. The market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of rise in awareness about this rare disorder along with the growing research activities in the region. The developing economies in the region, especially the countries such as China, India and Japan further provide significant opportunities to raise the demand for acute hepatic porphyria drugs.
Theacute hepatic porphyria drugs market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating the Market
The acute hepatic porphyria drugs market is dominated by market players such as Abbott Ltd. and Recordati Rare Diseases Inc. Moreover, several players in the pharmaceutical industry are increasingly expanding their product diversification by utilizing advanced healthcare technologies to develop drugs that would be suitable for all patients without causing any adverse side-effects on them. Additionally, market players are also hugely investing on research and developmental activities that would focus on treatment of rare diseases with the help of advancement in healthcare technologies.
